Nan Shan Life Insurance Co. Ltd. trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 23.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,870 shares of the life sciences company's stock after selling 13,123 shares during the quarter. Nan Shan Life Insurance Co. Ltd.'s holdings in Illumina were worth $5,729,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Bank of Stockton boosted its stake in shares of Illumina by 3.8% during the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after purchasing an additional 80 shares during the last quarter. Stephens Inc. AR grew its stake in Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock worth $885,000 after acquiring an additional 90 shares during the period. Spire Wealth Management raised its holdings in Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after acquiring an additional 97 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Illumina by 19.1% during the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock worth $82,000 after purchasing an additional 99 shares during the period. Finally, Freedom Investment Management Inc. grew its position in shares of Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after purchasing an additional 101 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have commented on ILMN shares. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Canaccord Genuity Group dropped their price target on Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research note on Monday. Piper Sandler lifted their price objective on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. JPMorgan Chase & Co. dropped their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Morgan Stanley reduced their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $130.95.
Check Out Our Latest Research Report on ILMN
Illumina Stock Performance
Shares of ILMN opened at $80.30 on Wednesday. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market cap of $12.71 billion, a price-to-earnings ratio of -10.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The firm has a fifty day moving average of $78.77 and a 200-day moving average of $112.48.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same period last year, the firm earned $0.98 EPS. The firm's revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
